Valeant investors doubting drugmaker's chief can regain grip
The company is in worse shape after Michael Pearson returned from a two-month medical leave for pneumonia
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Boston
MICHAEL Pearson and his company, Valeant Pharmaceuticals International Inc, were supposed to calm Wall Street doubters on Tuesday. Instead: chaos.
What began before dawn with disappointing financial news quickly snowballed into the worst day in the drug company's history, leaving investors wondering if Mr Pearson, its controversial chief, can regain his grip.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
